Answer:

There are three main studies indicating that Trecondi is at least as effective as busulfan, another drug used for hematopoietic stem cell transplantation in patients.

One study involved 570 adults with acute myeloid leukemia (a type of blood cancer) or myelodysplastic syndromes (a disease that produces a large number of abnormal blood cells). Among the patients treated with Trecondi (with fludarabine), 64% successfully underwent transplantation and were disease-free two years later, compared to 51% of those treated with busulfan (with fludarabine).

In another study involving 70 children with blood cancers, 99% of the children treated with Trecondi (with fludarabine) were still alive three months after transplantation; 91% were alive one year later, and 84% were alive three years later.

In a third study involving 101 children with other severe diseases requiring bone marrow transplantation, none of the 51 children treated with Trecondi died from transplant-related causes within three months of the procedure, whereas 5 out of 50 children treated with busulfan (with fludarabine) died. One year after transplantation, 96% of the children treated with Trecondi were still alive, compared to 88% of those treated with busulfan.